Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration
2014-000709-10Phase 4Completed
- Sponsor
- Universitätsklinikum Münster
- Start
- Oct 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of alemtuzumab in multiple sclerosis (MS), sponsored by Universitätsklinikum Münster. Primary endpoint: Peripheral blood immune cell counts. Started Oct 2014; status: completed.
02
Drugs
alemtuzumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2014-000709-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000709-10.